{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:07:16Z","timestamp":1784081236394,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Following a 30-year development process, RTS,S\/AS01<jats:sub>E<\/jats:sub> (GSK, Belgium) is the first malaria vaccine to reach Phase IV assessments. The World Health Organization-commissioned Malaria Vaccine Implementation Programme (MVIP) is coordinating the delivery of RTS,S\/AS01<jats:sub>E<\/jats:sub> through routine national immunization programmes in areas of 3 countries in sub-Saharan Africa. The first doses were given in the participating MVIP areas in Malawi on 23 April, Ghana on 30 April, and Kenya on 13 September 2019. The countries participating in the MVIP have little or no baseline incidence data on rare diseases, some of which may be associated with immunization, a deficit that could compromise the interpretation of possible adverse events reported following the introduction of a new vaccine in the paediatric population. Further, effects of vaccination on malaria transmission, existing malaria control strategies, and possible vaccine-mediated selective pressure on <jats:italic>Plasmodium falciparum<\/jats:italic> variants, could also impact long-term malaria control. To address this data gap and as part of its post-approval commitments, GSK has developed a post-approval plan comprising of 4 complementary Phase IV studies that will evaluate safety, effectiveness and impact of RTS,S\/AS01<jats:sub>E<\/jats:sub> through active participant follow-up in the context of its real-life implementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>EPI-MAL-002 (NCT02374450) is a pre-implementation safety surveillance study that is establishing the background incidence rates of protocol-defined adverse events of special interest. EPI-MAL-003 (NCT03855995) is an identically designed post-implementation safety and vaccine impact study. EPI-MAL-005 (NCT02251704) is a cross-sectional pre- and post-implementation study to measure malaria transmission intensity and monitor the use of other malaria control interventions in the study areas, and EPI-MAL-010 (EUPAS42948) will evaluate the <jats:italic>P. falciparum<\/jats:italic> genetic diversity in the periods before and after vaccine implementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>GSK\u2019s post-approval plan has been designed to address important knowledge gaps in RTS,S\/AS01<jats:sub>E<\/jats:sub> vaccine safety, effectiveness and impact. The studies are currently being conducted in the MVIP areas. Their implementation has provided opportunities and posed challenges linked to conducting large studies in regions where healthcare infrastructure is limited. The results from these studies will support ongoing evaluation of RTS,S\/AS01<jats:sub>E<\/jats:sub>\u2019s benefit-risk and inform decision-making for its potential wider implementation across sub-Saharan Africa.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04144-3","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T11:02:58Z","timestamp":1650884578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Assessing the safety, impact and effectiveness of RTS,S\/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up"],"prefix":"10.1186","volume":"21","author":[{"given":"Nicolas","family":"Praet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwaku Poku","family":"Asante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Cecile","family":"Bozonnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine Jacqueline","family":"Akit\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Odum","family":"Ansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Baril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owusu","family":"Boahen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda Guerra","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Haine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kariuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Maleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Mungwira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latif","family":"Ndeketa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Oduro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhards","family":"Ogutu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Olewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Oneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt\u00e9a","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith Roset","family":"Bahmanyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Rosillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lode","family":"Schuerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Sing\u2019oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne J.","family":"Terlouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"W\u00e9ry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pir\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"4144_CR1","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31\u201345.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"4144_CR2","unstructured":"European Medicines Agency. Mosquirix H-W-2300. Product information. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/document_listing\/document_listing_000395.jsp&mid=. Accessed 22 May 2020."},{"key":"4144_CR3","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1080\/21645515.2019.1586040","volume":"15","author":"Y Guerra Mendoza","year":"2019","unstructured":"Guerra Mendoza Y, Garric E, Leach A, Lievens M, Ofori-Anyinam O, Pircon JY, et al. Safety profile of the RTS, S\/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Hum Vaccin Immunother. 2019;15:2386\u201398.","journal-title":"Hum Vaccin Immunother"},{"key":"4144_CR4","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants. N Eng J Med. 2012;367:2284\u201395.","DOI":"10.1056\/NEJMoa1208394"},{"key":"4144_CR5","unstructured":"European Medicines Agency. Mosquirix H-W-2300. European Public Assessment Report. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/document_listing\/document_listing_000395.jsp&mid=. Accessed 19 March 2020."},{"key":"4144_CR6","unstructured":"Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec. 2016;91:33\u201351."},{"key":"4144_CR7","unstructured":"WHO. Q&A on the malaria vaccine implementation programme (MVIP). Geneva, World Health Organization. https:\/\/www.who.int\/malaria\/media\/malaria-vaccine-implementation-qa\/en\/. Accessed 22 January 2020."},{"key":"4144_CR8","unstructured":"WHO. Global Technical Strategy for Malaria 2016\u20132030. Geneva, World Health Organization, 2015. https:\/\/www.who.int\/malaria\/areas\/global_technical_strategy\/en\/. Accessed 19 March 2020. ."},{"key":"4144_CR9","unstructured":"Malaria vaccine: WHO position paper \u2013 March 2022. Wkly Epidemiol Rec. 2022;97 61\u201380."},{"key":"4144_CR10","unstructured":"WHO. Malaria: The malaria vaccine implementation programme (MVIP). Geneva, World Health Organization, 2020. Q&A. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/malaria-vaccine-implementation-programme. Accessed 08 March 2022."},{"key":"4144_CR11","unstructured":"WHO. Full evidence report on the RTS,S\/AS01 malaria vaccine. SAGE Yellow Book for October 2021. 5.1 malaria. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/mvip\/full-evidence-report-on-the-rtss-as01-malaria-vaccine-for-sage-mpag-(sept2021).pdf?sfvrsn=c9737be_5 Accessed 08 March 2022."},{"key":"4144_CR12","unstructured":"WHO. Key milestones in the development of the Malaria Vaccine Implementation Programme (MVIP): from pilot recommendation to vaccine introduction. Geneva, World Health Organization. https:\/\/www.who.int\/docs\/default-source\/immunization\/mvip\/mvip-milestones-to-programme-development-final.pdf?sfvrsn=14768db0_4. Accessed 16 March 2022."},{"key":"4144_CR13","unstructured":"ClinicalTrials.gov. Malaria vaccine evaluation programme (MVPE). 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03806465?term=vaccine&cond=Malaria&cntry=GH&age=0&draw=2&rank=7. Accessed 26 May 2021."},{"key":"4144_CR14","unstructured":"WHO. Ghana, Kenya and Malawi to take part in WHO malaria vaccine pilot programme. Geneva, World Health Organization, 2017. https:\/\/www.afro.who.int\/news\/ghana-kenya-and-malawi-take-part-who-malaria-vaccine-pilot-programme. Accessed 22 January 2020."},{"key":"4144_CR15","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd Edn. Geneva, World Health Organization, 2015. http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241549127\/en\/. Accessed 26 February 2019."},{"key":"4144_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/07474946.2011.539924","volume":"30","author":"M Kulldorff","year":"2011","unstructured":"Kulldorff M, Davis R, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Seq Anal. 2011;30:58\u201378.","journal-title":"Seq Anal"},{"key":"4144_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/oxfordjournals.aje.a115884","volume":"133","author":"ME Halloran","year":"1991","unstructured":"Halloran ME, Haber M, Longini IM Jr, Struchiner CJ. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol. 1991;133:323\u201331.","journal-title":"Am J Epidemiol"},{"key":"4144_CR18","doi-asserted-by":"crossref","unstructured":"RTS,S Epidemiology EPI-MAL-002 Study Group. Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S\/AS01(E) malaria vaccine. Malar J. 2021;20:197.","DOI":"10.1186\/s12936-021-03751-w"},{"key":"4144_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/1475-2875-11-380","volume":"11","author":"T Mzilahowa","year":"2012","unstructured":"Mzilahowa T, Hastings IM, Molyneux ME, McCall PJ. Entomological indices of malaria transmission in Chikhwawa district, Southern Malawi. Malar J. 2012;11:380.","journal-title":"Malar J"},{"key":"4144_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/1475-2875-8-276","volume":"8","author":"A Roca-Feltrer","year":"2009","unstructured":"Roca-Feltrer A, Schellenberg JR, Smith L, Carneiro I. A simple method for defining malaria seasonality. Malar J. 2009;8:276.","journal-title":"Malar J"},{"key":"4144_CR21","doi-asserted-by":"crossref","unstructured":"RTS,S Epidemiology EPI-MAL-005 Study Group. Estimating annual fluctuations in malaria transmission intensity and in the use of malaria control interventions in five sub-Saharan African countries. Am J Trop Med Hyg. 2020;103:1883\u201392.","DOI":"10.4269\/ajtmh.19-0795"},{"key":"4144_CR22","unstructured":"WHO. Malaria vaccine implementation programme: one year on. Geneva, World Health Organization, 2020. https:\/\/www.who.int\/immunization\/diseases\/malaria\/malaria_vaccine_implementation_programme\/en\/. Accessed 22 May 2020."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04144-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04144-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04144-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T07:06:05Z","timestamp":1653289565000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04144-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4144"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04144-3","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"4 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following the original publication of this article, the graphic abstract has been updated with the DOI information 10.1186\/s12936-022-04144-3, which had erreonously been omitted from the originally published version.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EJA, YGM, VH, FR, LS, SW and JYP are employees of the GSK group of companies.\u00a0At the time of the study NP was an employee of the GSK group of companies and is now employed by Janssen Pharmaceutica NV. At the time of the study DR was an employee of the GSK group of companies and is now a freelance consultant at DESiRE-Consulting. NP, YGM, ML, FR, LS, DR and JYP hold shares in the GSK group of companies. ML is employee of Aixial on behalf of the GSK group of companies. MOr and MCB are employees of 4Clinics on behalf of the GSK group of companies. KPA, POA, OB, SK, KM, RM, LN, AO, BO, FO, MOn, VS, DJT and WO via their institutions, received grants from the GSK group of companies for the conduct of this study\/work. KPA, OB, SK, WO, VS, KM and DJT via their institutions, received grants from the GSK group of companies for the conduct of studies outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}